Skip to main content
Premium Trial:

Request an Annual Quote

Foundation, Array BioPharma Partner to ID Suitable Patients for Cancer Drugs

NEW YORK (GenomeWeb News) – Foundation Medicine announced today it is collaborating with Array BioPharma to assess patients who may be best suited for treatment with oncology treatments being developed by Array.

Foundation will use its genomic sequencing and analytical capabilities to evaluate potentially relevant molecular interactions that may shed light on patient response to Array's treatments. Array has a portfolio of targeted cancer treatments in the early stages of clinical development, and through the partnership it hopes to determine the genetic profile of tumors of patients treated with certain of its treatments.

The companies did not disclose which cancers are targeted by the partnership. Financial and other terms of the deal also were not disclosed.

Based in Cambridge, Mass., Foundation recently received CLIA certification for its laboratory. Last month, it and researchers from the Dana Farber Cancer Institute said they demonstrated that the company's assay being developed for cancer diagnostics can identify clinically actionable mutations from tumor samples.